The short answer is that the approved sites are the same across all subcutaneous GLP-1 receptor agonists, but there are some practical differences worth noting
Why Does OrderlyMeds Require Text-Message Opt-In
Of the 2,570 MOUNJARO-treated patients who developed anti-tirzepatide antibodies during the treatment periods in these seven trials, 2% and 2% developed neutralizing antibodies against tirzepatide activity on the GIP or GLP-1 receptors, respectively, and 0.9% and 0.4% developed neutralizing antibodies against native GIP or GLP-1, respectively
Heat above 86F (30C) for extended periods can degrade the peptide
How do I get my brain out of a fog
Eggs, especially the yolks, also provide B12